FDA approves Tecentriq in combination with Cotellic and Zelboraf for patients with advanced skin cancer

01/12/2021 By Dr. Dan Platt

Summary: The Food and Drug Administration (FDA) announced the approval of a new combination of three different drugs for the treatment of patients with BRAF V600 mutation-positive advanced melanoma. The new regimen combines an immunotherapy, Tecentriq (atezolizumab), with two targeted therapies, Cotellic (cobimetinib) and Zelboraf (vemurafenib).

Dr. Dan’s Takeaway: Adding Tecentriq to the combination of two approved targeted therapies extended survival from 10.6 months to 15.1 months in patients with advanced melanoma with a BRAF mutation. This is the first approval of these three types of drugs used in combination, but others will soon follow.



Deskside with Dr. Dan

“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

– Dan Platt, M.D.

Chief Medical Officer

About The Poster

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore the latest Hub posts


Somewhere Before & After: Schrödinger’s Cancer

Ellis defined the space between when you had testing and biopsies done and when you finally get results as Schrödinger’s Cancer. The Gryt Health team is republishing and resharing this piece on August 13, 2022, as we remember and honor Ellis’ life with a Virtual Celebration of Life. Ellis Emerson (1985-2022)

Tell Your Story

Maria Farah’s Story

Breast cancer survivor Maria shares what Gryt Is as a person diagnosed at 28.

Want Email Updates?

Get updates in your inbox when new content is posted on the website.

Find value in this post? Please share!

Share on facebook
Share on linkedin
Share on twitter
Share on email

You are never alone

View our resources for those who are experiencing, have experienced, or are supporting someone who has experienced a medical diagnosis.